Cantor Fitzgerald reiterates Atrium Therapeutics stock Overweight
Alpha Vantage · Investing.com · · AI-summarised by FinFlash
Cantor Fitzgerald reiterated an Overweight rating and $25.00 price target on Atrium Therapeutics (NASDAQ:RNA) after a $50 million private placement expected to extend the company's cash runway through 2028. The firm argues the market is significantly undervaluing the stock, which trades at roughly negative Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.Understand the context